Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in
Abstract:
An isocratic reversed phase HPLC method for the simultaneous determination of doxorubicine (DOX) and celecoxib (CXB) out of a nanoparticulate fixed dose combination (NanoFDC) was developed and validated. Linearity of the results was demonstrated from 1-11 μg/mL for both components. Lower limits of detection were determined as 7 ng/mL for DOX and 13 ng/mL for CXB. Total run time was approximately 15 min.
Related Concept Videos
Dose Size and Dosing Frequency: Determination Methods
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Reliability and Validity
In Vitro Drug Release Testing: Overview, Development and Validation
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations


